Already a member? Sign in
Ziprasidone is used to treat the symptoms of schizophrenia. It is also used to treat episodes of mania or mixed episodes in people with bipolar disorders. It is in a class of medical called atypical antipsychotics.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Bipolar Disorder | 89 | 52 |
|
|
|
|
|
| Treat my mood condition(s) | 57 | 17 |
|
|
|
|
|
| Borderline Personality Disorder | 12 | 3 |
|
|
|
||
| Bipolar II Disorder | 12 | 4 |
|
|
|
|
|
| Bipolar I Disorder | 9 | 4 |
|
|
|
||
| Hallucinations | 9 | 3 |
|
|
See all 182 patients currently taking Ziprasidone
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Ziprasidone
| Sleepiness | 28 | |
|---|---|---|
| Internal Restlessness (Akathisia) | 15 | |
| Tremor in hands | 11 | |
| Headaches | 8 | |
| Excessive daytime sleepiness (somnolence) | 7 | |
| Tardive dyskinesia | 6 | |
| See all 101 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Ziprasidone. See all 17 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 57 | ||
| Doctor's advice | 23 | ||
| Did not seem to work | 22 | ||
| Expense | 5 | ||
| Other | 4 | ||
| Personal research | 3 | ||
| Course of treatment ended | 2 |
Adherence
Taking treatment as prescribed
Adherence of Ziprasidone
Always |
87 | 86% |
|
|---|---|---|---|
Usually |
7 | 7% |
|
Sometimes |
4 | 4% |
|
Never |
3 | 3% |
|
Burden
Difficulty being on treatment
Burden of Ziprasidone
Very |
20 | 20% |
|
|---|---|---|---|
Somewhat |
14 | 14% |
|
A little |
10 | 10% |
|
Not at all |
57 | 56% |
|
Cost
Paid out of pocket
Cost of Ziprasidone
$200+ |
6 | 9% |
|
|---|---|---|---|
$100-199 |
7 | 10% |
|
$50-99 |
14 | 21% |
|
$25-49 |
8 | 12% |
|
< $25 |
32 | 48% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 11, 2012.